ArticleNeurocritical care2026
Pediatric MOGAD in the Intensive Care Unit: A Case Series.
Article in Neurocritical care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyelin oligodendrocyte glycoprotein antibody disease (MOGAD) is an antibody mediated demyelinating disorder of the central nervous system with a spectrum of clinical presentations and severity, including a subgroup of patients requiring admission to an intensive care unit (ICU) due to severity of their disease. While there is a growing body of literature on MOGAD, there are limited reports focusing on patients requiring admission to an ICU. The aim of this study was to better characterize a population of pediatric patients with MOGAD with critical illness, focusing on patients requiring ICU admission.
methodsA retrospective chart review was performed on pediatric patients with MOGAD between January 2017 and December 2024 at a large pediatric tertiary care center. Clinical, laboratory, and imaging data were collected for all patients with MOGAD. Magnetic resonance neuroimaging was reviewed by a board-certified pediatric neuroradiologist.
resultsOf the 124 pediatric patients with MOGAD identified, 37 required ICU admission for either altered mental status, seizures, and/or rapid onset of weakness. Of those requiring ICU admission, 16 were intubated due to altered mental status or seizures for a median duration of 3 days (IQR 2-10.8 days). Fever was common, present in 24 of the patients in the ICU. Seven patients received intracranial pressure (ICP)-directed hyperosmolar therapy, and two patients had an ICP monitoring device placed. In total, 12 patients had neuroimaging evidence of increased ICP, with 4 of these having evidence of herniation or cerebral shift. Seizures were present in 18 patients, and 11 patients had status epilepticus. There were 27 patients who had continuous electroencephalography (cEEG) monitoring with a heterogeneity of background patterns observed.
conclusionsSevere presentations of MOGAD are increasingly recognized, including patients with a clinical course complicated by status epilepticus or increased ICP. Anticipating and addressing these complications may prevent secondary cerebral injury. No specific EEG biomarkers for MOGAD were observed in our cohort.
Indexed as
Identifiers
42768270What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.